Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab
Authors:
- 24 November 2020
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 70 (6) , 1593-1603
Abstract
Background We investigated the combined effects of sarcopenia and inflammation on outcomes in patients with HCC treated with nivolumab. Materials and Methods We reviewed 102 patients treated with nivolumab between 2017 and 2018. Sarcopenia was diagnosed when the L3 skeletal muscle indices were < 42 cm2/m2 and < 38 cm2/m2 in men and women, respectively. Baseline neutrophil-to-lymphocyte ratio (NLR) and absolute lymphocyte count were used as surrogate markers of inflammation and immune cell reservoir. High NLR (hNLR) was defined as NLR ≥ 3, and severe lymphopenia (sLP) was defined as lymphocyte < 800/μL. The overall survival (OS) and progression-free survival (PFS) were analyzed. Results With a median follow-up of 21.9 (interquartile range, 8.3–58.3) months, patients with sarcopenia showed shorter OS than those without sarcopenia (median, 2.9 vs. 7.5 months, respectively). Patients with either hNLR or sLP exhibited inferior survival than those without risk factor (median OS, 2.8 vs. 14.5 months; median PFS, 1.3 vs. 3.7 months, respectively). Among 70 patients treated with RT, benefit of RT was observed in patients with sarcopenia or those without hNLR/sLP (all p < 0.05). After multivariable analysis, RT, hNLR/sLP, albumin–bilirubin (ALBI) grade, and alpha-fetoprotein were significantly associated with OS (all p < 0.05), and hNLR/sLP was also associated with decreased PFS together with ALBI grade, alpha-fetoprotein, and RT (all p < 0.05). Conclusion The current study hypothetically demonstrated that the risk group stratified by hNLR/sLP outweighs the significance of sarcopenia in predicting outcomes after nivolumab. Furthermore, patients with sarcopenia might benefit from RT, especially those without risk factors of hNLR/sLP.Keywords
Funding Information
- National Research Foundation Korea (NRF-2020R1F1A1073205)
This publication has 37 references indexed in Scilit:
- The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanomaBritish Journal of Cancer, 2017
- Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor ImmunityCell Metabolism, 2016
- Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelinesRadiation Oncology Journal, 2016
- Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteriaHepatology Research, 2016
- Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapyEuropean Journal of Cancer, 2016
- Excess TGF-β mediates muscle weakness associated with bone metastases in miceNature Medicine, 2015
- Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-AnalysisJNCI: Journal of the National Cancer Institute, 2014
- Muscle Wasting in Cancer Cachexia: Clinical Implications, Diagnosis, and Emerging Treatment StrategiesAnnual Review of Medicine, 2011
- Systemic effects of local radiotherapyThe Lancet Oncology, 2009
- Sarcopenia: Effects on Body Composition and FunctionThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2003